Hospital acquired infections, or healthcare-associated infections (HAI) are nosocomially acquired infections that are typically absent or might be incubated at admission. Hospital acquired infections are usually acquired after hospitalization and apparent 48 hours after admission to the hospital. The infections are supervised intently by agencies for instance the National Healthcare Safety Network (NHSN) of the Center for Disease Control and Prevention (CDC). The supervision of hospital acquired infections is done in order to prevent HAI and improve patient safety in healthcare institutions and organization. HAI infections comprise hospital-acquired pneumonia (HAP), central line-associated bloodstream infections (CLABSI), ventilator-associated pneumonia (VAP), surgical site infections (SSI), catheter-associated urinary tract infections (CAUTI), and clostridium difficile infections (CDI). In the last few years, hospitals have taken the hospital acquired infections seriously as the riinsg prevalence of such infections are being the major cause of mortality. Several hospitals have established infection tracking and surveillance systems and robust prevention strategies to reduce the rate of hospital-acquired infections. The impact of hospital acquired infections is seen not just at an specific one patient level but also at the group level, as they have been linked to multidrug-resistant infections. Identifying patients with risk factors for hospital-acquired and multidrug-resistant infections is crucial in preventing and minimizing these infections. Furthermore, there are various types of treatment options for hospital acquired infections, that depends on the severity of the infection and the causative agent.
The "Global Hospital acquired infection treatment market analysis to 2030" is a specialized and in-depth study of the pharmaceutical industry with a special focus on global market trend analysis. The report aims to provide an overview of the hospital acquired infection treatment market with detailed market segmentation by drug class, infection type, and geography. The report provides key statistics on the market status of the leading hospital acquired infection treatment market players and offers key trends and opportunities in the market.
The hospital acquired infection treatment market is segmented based on drug class, infection type, and region. Based on drug type, the global hospital acquired infection treatment market is differentiated into antibacterial drugs, antiviral drugs, and antifungal drugs. By infection type, the hospital acquired infection treatment market is classified into urinary tract infections, ventilator-associated pneumonia, surgical site infections, bloodstream infections and other hospital infections.
In the coming years, it is anticipated that the high prevalence of HAIs is expected to increase the demand for effective treatment to ensure complete and speedy recovery which in turn driving the market growth. According to the Organisation for Economic Co-operation and Development (OECD), every year, about 3.8 million people in EU nations contract an infection related to healthcare in acute care hospitals. The same source also claims that every year, approximately 90,000 people in EU nations died due to HAIs. The high incidence of HAI and rising antibiotic resistance have considerably increased the demand for new HAI therapies. As a result, prominent market players engage in extensive R&D efforts to create new HAI medications and secure their acceptance in important markets. In May 2023, Indian Institute of Science Education and Research (IISER) in Pune, and Council of Scientific & Industrial Research-Central Drug Research Institute (CSIR-CDRI), Lucknow has jointly discovered a antibiotic to cure hospital acquired infections.
Furthrmore, rising incidence of chronic conditions like cancer, heart disease, diabetes, and arthritis have increased the health concerns at global level. The American Cancer Society reported data showing that there were around 1.9 million new cancer cases worldwide in 2022. The number of hospital admissions has increased as a result of the increasing incidence of these chronic diseases which has further increased the incidence and prevalence of HAIs among these patients. For instance, the New York State Department of Health reported in November 2019 that around 40% of adults in the state have a chronic illness, which accounts for approximately 23% of all hospitalisations.
North America accounts for largest revenue share in global hospital acquired infection treatment market in 2022. The high cost of hospital acquired infection treatment, as well as the increased awareness and affordability of the population in the region is expected to anticipate the market growth. Europe is expected to be the second largest market in hospital acquired infection treatment market and expected to closely follow the North America in coming years. The high frequency of hospital acquired infection treatment in European nations and the rising approval and introduction of innovative hospital acquired infection treatment medications in the region is expected to amplify the market growth. Moreover, region has the preesnce of various local market players operation in the market such as GlaxoSmithKline Plc, F. Hoffmann-La Roche AG, Allergan Plc, and Bayer AG providingaccessibility of novel hospital-acquired infection treatments in European nations.
Asia Pacific is expected to show significant growth owing the presence of developing economies such as India, China and others that has increased prevelance of HAIs are driving the market growth in the region. Additionally, hospitalisation rates have increased due to the rising frequency of chronic diseases in developing nations like China and India. For instance, according to data from Springer Nature, there were approximately 2.7 million new cancer cases diagnosed in China in 2022. Therefore, increasing hopsitalizations due to chronic disease has further amplified the prevelance of HAIs which in turn contributing to the hospital acquired infection treatment market growth.
The report covers key hospital acquired infection treatment market developments, such as organic and inorganic growth strategies. Various companies such as Merck and Co., Inc., Pfizer Inc., Bayer AG, GlaxoSmithKline Plc., Daiichi Sankyo Company, Limited, AbbVie Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd, Allergan Plc., AstraZeneca and among others are focusing on organic growth strategies such as product launches, product approvals, and others such as patents and events. Inorganic growth strategies activities witnessed in the hospital acquired infection treatment market were acquisitions, partnerships & collaborations. These activities have paved the way for the expansion of business and the customer base of hospital acquired infection treatment market players. The market players from the hospital acquired infection treatment market are anticipated to have lucrative growth opportunities with the rising demand for hospital acquired infection treatment in the global market.
Key Developments in Global Hospital acquired infection treatment market
- In May 2023, Innoviva Specialty Therapeutics received FDA approval for Xacduro, it's a new antibiotics which used to treat hospital acquired infection.
- In May 2023, Indian Institute of Science Education and Research (IISER) in Pune, and Council of Scientific & Industrial Research-Central Drug Research Institute (CSIR-CDRI), Lucknow has jointly discovered a antibiotic to cure hospital acquired antibiotic.
- In June 2020, Merck get FDA approval for Recarbrio. It advances the treatment for hospital-acquired infections, such as ventilator-associated bacterial pneumonia, caused by difficult to treat Gram-negative organisms.
- In June 2019, FDA has approved new treatment for hospital-acquired and ventilator-associated bacterial pneumonia.
The hospital acquired infection treatment market report also includes key companies' profiles, their SWOT analysis, and hospital acquired infection treatment market size and strategies. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information for the last three years, and key development in the past five years.
The Insight Partner's dedicated research and analysis team comprises experienced professionals with advanced statistical expertise and offers various customization options in the current study.
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
This text is related
to segments covered.
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
This text is related
to country scope.
The List of Companies
1. MERCK AND CO., INC.
2. PFIZER INC.
3. BAYER AG
4. GLAXOSMITHKLINE PLC.
5. DAIICHI SANKYO COMPANY
6. LIMITED, ABBVIE INC.
7. ABBOTT LABORATORIES
8. F. HOFFMANN-LA ROCHE LTD
9. ALLERGAN PLC.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Drug Delivery Market
Forecast to 2028 - Global Analysis By Route of Administration (Injectable Drug Delivery, Oral Drug Delivery, Transmucosal Drug Delivery, Topical Drug Delivery, Implantable Drug Delivery, and Ocular Drug Delivery), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and End User (Hospitals and Clinics, Home Care Settings, and Other End User)
Enteral and Parenteral Medical Nutrition Market
Forecast to 2028 - Global Analysis by Indication [Elderly, Gastrointestinal Disorders (IBD, IBS, and Others), Diabetes, Cancer, Respiratory Disorders, Alzheimer's Disease, Dementia, Renal Disease, Liver Failure, Post COVID-19, and Other Indications], Nutrition Type (Supplemental and Sole–Source), Form (Liquid, Powder, and Semi–Solid), Product Type (General and Disease–Specific), Route of Administration (Oral, Tube Feed, and Parenteral), Age Group (Above 60 Years, 18–60 Years, 3–18 Years, and Below 3 Years), and Distribution Channel (Hospital Pharmacies, Retail Stores, E-Commerce, and Others)
CIN & HR-HPV Treatment Market
Forecast to 2028 - Global Analysis By Disease Type (Cervical Intraepithelial Neoplasia 1, Cervical Intraepithelial Neoplasia 2, and Cervical Intraepithelial Neoplasia 3), Strain Type (HPV 16, HPV 18, and Others), Offering (Diagnostic Method and Treatment), Product Type (Kits & Reagents, Instruments, and Services), and End User (Hospitals & Clinics, Diagnostic Laboratories, Specialized Clinical Laboratories, and Others)
Pharmaceutical Fluid Handling Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Offering (Equipment & Solutions and Services), Tubing (Thermoplastic Elastomers, Polyvinyl Chloride, and Silicone), Application (Fluid Handling & Management, Fluid Preparation, Integration & Automation, Buffer Management, and Others), Usage (Cough Syrup, Intravenous Product, Complex Active Pharmaceutical Ingredients, and Others), and End User (Biotechnology Companies, Pharmaceutical & Medical Companies, and Others)
Enteral Medical Nutrition Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Indication (Respiratory Disorders, Cancer, Post COVID-19, Gastrointestinal Disorders, Liver Failure, and Others), Nutrition Type (Supplemental and Sole-Source), Form (Powder, Liquid, and Semi-Solid), Product (Standard Protein Diet, High Protein Diet, Fruit Juice Based Oral Nutritional Supplement, and Others), Distribution Channel (Hospital Pharmacies, Retail Stores, and Others), and Age Group [Child (Till 18 Years) and Adults (18+years)]
Glycomic Therapeutics Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Class (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins & Heparin Based Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), and Mode of Action [Inhibits Neuraminidase; Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate; Erythropoietin & Enzyme Replacement Therapy (ERT); Tissue Plasminogen Activator; Inhibits Glucosylceramide Synthase; Interleukin 1, 2 & 3; Beta & Gamma Interferons; and Others]